Synopsis Isolated clinical case studies have reported that latanoprost had adverse events in pediatric patients. However, such studies were not sufficient to provide adequate consolidation into the matter. The present cohort study thus evaluates the long-safety safety of latanoprost in pediatric patients with glaucoma and ocular hypertension. This week’s “MED FACT” discusses a clinical study from American Journal of Ophthalmology, “A Long-term Safety Study of Latanoprost in Pediatric Patients with Glaucoma and Ocular Hypertension: A Prospective Cohort Study” . Authors : Muhammad Younus, Ronald A.
Schachar, Min Zhang, Marla B. Sultan et al. Key Takeaways: Latanoprost had an adequate safety profile in pediatric patients with glaucoma and ocular hypertension. Objective: To evaluate the safety of Latanoprost in pediatric with glaucoma and ocular hypertension Study Type: Cohort Study (LYNX…
